Download PDF
Drug Res (Stuttg) 2015; 65(10): 532-534
DOI: 10.1055/s-0034-1390419
Original Article
© Georg Thieme Verlag KG Stuttgart · New York

DPP-4 Inhibitor Teneligliptin Improves Insulin Resistance and Serum Lipid Profile in Japanese Patients with Type 2 Diabetes

M. Kusunoki
1   Department of Internal Medicine, Medical Clinic, Aichi Medical University, Nagoya, Japan
,
D. Sato
2   Department of Biomedical Information Engineering, Graduate School of Medical Science, Yamagata University, Yamagata, Japan
,
T. Nakamura
2   Department of Biomedical Information Engineering, Graduate School of Medical Science, Yamagata University, Yamagata, Japan
,
Y. Oshida
3   Research Center of Health, Physical Fitness and Sports, Nagoya University, Nagoya, Japan
,
H. Tsutsui
4   Department of Hygiene and Public Health, Teikyo University School of Medicine, Tokyo, Japan
,
Y. Natsume
5   Department of Sports Medicine, Graduate School of Medicine, Nagoya University, Nagoya, Japan
,
K. Tsutsumi
6   Okinaka Memorial Institute for Medical Research, Tokyo, Japan
,
T. Miyata
7   Vascular Center, Sanno Medical Center, Tokyo, Japan
› Author Affiliations
Further Information

Publication History

received 30 July 2014

accepted 05 September 2014

Publication Date:
04 November 2014 (online)

Also available at
    Permissions and Reprints

Abstract

Dipeptidyl peptidase-4 (DPP-4) inhibitors have been reported to improve the glycemic control and blood hemoglobin A1c (HbA1c) concentrations. However, there are few reports as yet suggesting that DPP-4 inhibitors may also improve insulin resistance and the serum lipid profile in the clinical setting. This study was aimed at investigating the effect of 14-week treatment with teneligliptin (20 mg/day) on the homeostasis model assessment ratio (HOMA-R), an indicator of insulin resistance, and serum lipid profile in 9 patients with type 2 diabetes. The treatment produced a significant decrease of the blood glucose and HbA1c concentration (blood glucose: p=0.008; HbA1c: p=0.038), and also improved HOMA-R (p=0.039). Furthermore, the patients showed elevation of the serum HDL-cholesterol level (p=0.032), and a tendency towards reduction of the serum triglyceride level. The results indicate that teneligliptin acts not only to improve the blood glucose control, but also to improve the insulin resistance and serum lipid profile in Japanese type 2 diabetes patients.

Key words

teneligliptin - dipeptidyl peptidase-4 inhibitor - insulin resistance - HDL-cholesterol - triglyceride
 

  • References

  • 1 Kreymann B, Williams G, Ghatei MA et al. Glucagon-like peptide-1 7-36: a physiological incretin in man. Lancet 1987; 2: 1300-1304
    PubMedSearch in Google Scholar
  • 2 Edwards CM, Todd JF, Mahmoudi M et al. Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans: studies with the antagonist exendin 9-39. Diabetes 1999; 48: 86-93
    CrossrefPubMedSearch in Google Scholar
  • 3 Holst JJ, Deacon CF. Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663-1670
    CrossrefPubMedSearch in Google Scholar
  • 4 Lambeir AM, Durinx C, Scharpé S et al. Dipeptidyl-peptidase IV from bench to beside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci 2003; 40: 209-294
    CrossrefPubMedSearch in Google Scholar
  • 5 Kern M, Klöting N, Niessen HG et al. Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity. PLoS One 2012; 7: e38744
    CrossrefPubMedSearch in Google Scholar
  • 6 Nakaya K, Kubota N, Takamoto I et al. Dipeptidyl peptidase-4 inhibitor anagliptin ameliorates diabetes in mice with haploinsufficiency of glucokinase on a high-fat diet. Matabolism 2013; 62: 939-951
    PubMedSearch in Google Scholar
  • 7 Fukuda-Tsuru S, Kakimoto T, Utsumi H et al. The novel dipeptidyl peptidase-4 inhibitor teneligliptin prevents high-fat diet-induced obesity accompanied with increased energy expenditure in mice. Eur J Pharmacol 2014; 723: 207-215
    CrossrefPubMedSearch in Google Scholar
  • 8 Shirakawa J, Fujii H, Ohnuma K et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes 2011; 60: 1246-1257
    CrossrefPubMedSearch in Google Scholar
  • 9 Bomfeldt KE, Tabas I. Insulin resistance, hyperglycemia, and atherosclerosis. Cell Metab 2011; 14: 575-585
    CrossrefPubMedSearch in Google Scholar
  • 10 Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep 2011; 13: 544-552
    CrossrefPubMedSearch in Google Scholar
  • 11 Taskinen MR. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733-749
    CrossrefPubMedSearch in Google Scholar
  • 12 Hanefeld M, Fischer S, Julius U et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the diabetes intervention study, 11-year follow-up. Diabetologia 1996; 39: 1577-1583
    CrossrefPubMedSearch in Google Scholar
  • 13 Nakagami T. DECODA Study Group . Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004; 47: 385-394
    CrossrefPubMedSearch in Google Scholar
  • 14 Ervinna N, Mita T, Yasunari E et al. Anagliptin, a DPP-4 inhibitor, suppresses proliferation of vascular smooth muscles and monocyte inflammatory reaction and attenuates atherosclerosis in male apo E-deficient mice. Endicronology 2013; 154: 1260-1270
    PubMedSearch in Google Scholar
  • 15 Kadowaki T, Kondo K. Efficacy, safety and dose-response relationship of teneligliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus. Diabetes Obes Metab 2013; 15: 810-818
    CrossrefPubMedSearch in Google Scholar
  • 16 Nonaka K, Kakikawa T, Sato A et al. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008; 79: 291-298
    CrossrefPubMedSearch in Google Scholar
  • 17 Shimasaki T, Masaki T, Mitsutomi K et al. The dipeptidyl peptidase-4 inhibitor des-fluoro-sitagliptin regulates brown adipose tissue uncoupling protein levels in mice with diet induced obesity. PLoS One 2013; 8: e63626
    CrossrefPubMedSearch in Google Scholar
  • 18 Masuda T, Fu Y, Eguchi A et al. Dipeptidyl peptidase IV inhibitor lowers PPARγ agonist-induced body weight gain by affecting food intake, fat mass, and beige/brown fat but not fluid retention. Am J Physiol Endocrinol Metab 2014; 306: E388-E398
    CrossrefPubMedSearch in Google Scholar
  • 19 Moritoh Y, Takeuchi K, Asakawa T et al. Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and β-cell function in db/db mice. Br J Pharmacol 2009; 157: 415-426
    CrossrefPubMedSearch in Google Scholar
  • 20 Kubota T, Kubota N, Kumagai H et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab 2011; 13: 294-307
    CrossrefPubMedSearch in Google Scholar
  • 21 Nakagami H, Pang Z, Shimosato T et al. The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertens Res 2014; 37: 629-635
    CrossrefPubMedSearch in Google Scholar
  • 22 Monami M, Lamanna C, Desideri CM et al. DPP-4 inhibitors and lipids: systematic review and meta-analysis. Adv Ther 2012; 29: 14-25
    CrossrefPubMedSearch in Google Scholar
  • 23 Kusunoki M, Hara T, Tsutsumi K et al. The lipoprotein lipase activator, NO-1886, suppresses fat accumulation and insulin resistance in rats fed a high-fat diet. Diabetologia 2000; 43: 875-880
    CrossrefPubMedSearch in Google Scholar